Answers are grounded in this paper and cite their sources.
NRF2 is a key regulatory transcription factor that protects cells against oxidative stress and has been linked to the pathology of disorders such as Alzheimer’s disease. However, traditional measurement techniques for quantification of NRF2 lack the sensitivity required to detect endogenous levels of NRF2. Here, we present a highly sensitive SiMoA-(single molecule array) based assay for accurately detecting low levels of NRF2. The affinity and stability of the antibodies were analyzed using surface plasmon resonance (SPR). An antibody pair with a high affinity and binding stability for NRF2 was used to develop a SiMoA-based NRF2 assay. The developed assay was validated by analyzing its variability, reproducibility, detection limit and lower limit of quantification. The findings revealed that the SiMoA-based NRF2 assay can precisely quantify lower levels of NRF2 in cell culture samples, with a detection limit of 2.356 pg/mL. In addition, we assessed NRF2 levels in patients with Alzheimer’s disease and healthy controls. While the SiMoA-based NRF2 assay can quantify NRF2 levels in PBMC samples from patients, conventional ELISA could not measure NRF2 levels. Due to the high precision of the assay and its use with clinical samples, the assay has strong potential for use in clinical studies for diagnosis, evaluation of drug efficacy and patient monitoring.
No takes yet. Share an insight, caveat, or question.
Cotuk et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: